Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma

Lung Cancer

Volumn 66, Issue 3, 2009, Pages 292-297

  Sangodkar, Jaya ^a   DiFeo, Analisa ^a   Feld, Lauren ^a   Bromberg, Romina ^a   Schwartz, Rachel ^a   Huang, Fei ^a   Terzo, Esteban A ^a   Choudhri, Aisha ^a   Narla, Goutham ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy resistance; Lung cancer; Mouse models; Oncogene

Indexed keywords

CASPASE 3; CASPASE 8; CISPLATIN; KRUPPEL LIKE FACTOR 6; KRUPPEL LIKE FACTOR 6 SPLICE VARIANT 1; PROTEIN MCL 1; PROTEIN NOXA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC;

EID: 68949206913     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.014     Document Type: Article

References (21)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 55 (2005) 10-30
2. Strauss G.M. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. Hematol Oncol Clin North Am 19 (2005) 263-281
3. Farray D., Mirkovic N., and Albain K.S. Multimodality therapy for stage III non small-cell lung cancer. J Clin Oncol 23 (2005) 3257-3269
4. Olaussen K.A., Mountzios G., and Soria J.C. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm 13 (2007) 284-289
5. Modok S., Mellor H.R., and Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6 (2006) 350-354
6. Narla G., Heath K.E., Reeves H.L., et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294 (2001) 2563-2566
7. Reeves H.L., Narla G., Ogunbiyi O., et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126 (2004) 1090-1103
8. Kremer-Tal S., Reeves H.L., Narla G., et al. Frequent inactivation of the tumor suppressor kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 40 (2004) 1047-1052
9. Cho Y.G., Kim C.J., Park C.H., et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 24 (2005) 4588-4590
10. DiFeo A., Narla G., Hirshfeld J., et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 12 (2006) 3730-3739
11. Jeng Y.M., and Hsu H.C. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 105 (2003) 625-629
12. Kettunen E., Anttila S., Seppanen J.K., et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 149 (2004) 98-106
13. Ito G., Uchiyama M., Kondo M., et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 64 (2004) 3838-3843
14. Yamashita K., Upadhyay S., Osada M., et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2 (2002) 485-495
15. Hirasawa Y., Arai M., Imazeki F., et al. Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma. Oncology 71 (2006) 77-85
16. Narla G., Difeo A., Reeves H.L., et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65 (2005) 1213-1222
17. Narla G., DiFeo A., Yao S., et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 65 (2005) 5761-5768
18. Beer D.G., Kardia S.L.R., Huang C.C., et al. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 (2002) 816-824
19. DiFeo A., Feld L., Rodriguez E., et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res 68 (2008) 965-970
20. DiFeo A, Narla G, Huang F, et al. Inhibition of KLF6-SV1 increases ovarian cancer survival through the regulation of NOXA, Cancer Res, in press.
21. Narla G., DiFeo A., Fernandez Y., et al. KLF6-SV1 is a key regulator of metastasis and survival in prostate cancer. J Clin Invest 118 (2008) 2711-2721